The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative
pathogen of a new infectious disease, coronavirus disease 2019 (COVID-19), that first …

The presence of coagulopathy as part of the systemic inflammatory response syndrome is a
characteristic feature of severe coronavirus disease 2019 (COVID-19). Hematological …

The coronavirus disease 2019 (COVID-19) shows high incidence of thromboembolic events
in humans. In the present study, we aimed to evaluate if anticoagulation prior to COVID-19 …

Background There is no current standardized approach to anticoagulation in patients with
Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study …

There were initially three clear lines of evidence in support of an association between
thrombosis and coronavirus disease 2019 (COVID-19), as caused by SARS-CoV-2 (severe …

Hospitalized patients with coronavirus disease 2019 (COVID-19), particularly those admitted
to the intensive care unit (ICU) are at high risk of morbidity and mortality. Several …

Background Thromboprophylaxis of COVID-19 patients is a highly debated issue. We aimed
to compare the occurrence of thrombotic/ischemic events in COVID-19 patients with acute …

Objectives Thrombosis is a common complication of the novel COVID-19. Pre-COVID-19
studies reported racial differences in the risk of developing thrombosis. This study aimed to …

Background Evidence increasingly shows that the risk of thrombotic complications in COVID-
19 is associated with a hypercoagulable state. Several organizations have released …

Background SARS-CoV-2 infection has noted derangements in coagulation markers along
with significant thrombotic complications. Post-mortem examinations show severe …